$1,318.00
The approved drugs in the hypogonadism space target androgen receptors, estrogen receptor alpha, and estrogen receptor beta. These are commonly administered via the transdermal route, with a smaller number of products being available in oral, intramuscular, intranasal, sublingual/oral transmucosal, subcutaneous, and topical formulations.
This Market Spotlight report covers the Hypogonadism market, comprising key marketed and pipeline drugs, clinical trials, probability of success, epidemiology, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
7 Subtypes
8 TREATMENT
8 Treatment of hypogonadism in females
8 Treatment of hypogonadism in males
9 EPIDEMIOLOGY
10 MARKETED DRUGS
14 PIPELINE DRUGS
18 PROBABILITY OF SUCCESS
19 LICENSING AND ASSET ACQUISITION DEALS
19 Tolmar Acquires Hypgonadism Drug Jatenzo From Clarus Therapeutics
19 Another UK Biotech Snapped Up As Neurocrine Buys Diurnal
19 Bayer Sells Nebido To Grünenthal Amid Shift In Focus To Cell And Gene Pipeline
19 Halozyme Buys Antares, Expanding Drug Delivery Ambitions
21 REVENUE OPPORTUNITY
23 CLINICAL TRIAL LANDSCAPE
24 Sponsors by status
25 Sponsors by phase
27 BIBLIOGRAPHY
28 APPENDIX
LIST OF FIGURES
14 Figure 1: Overview of pipeline drugs for hypogonadism in the US
14 Figure 2: Pipeline drugs for hypogonadism, by company
14 Figure 3: Pipeline drugs for hypogonadism, by drug type
15 Figure 4: Pipeline drugs for hypogonadism, by classification
18 Figure 5: Probability of success in the hypogonadism pipeline
23 Figure 6: Clinical trials in hypogonadism
23 Figure 7: Top 10 drugs for clinical trials in hypogonadism
24 Figure 8: Top 10 companies for clinical trials in hypogonadism
24 Figure 9: Trial locations in hypogonadism
25 Figure 10: Hypogonadism trials status
26 Figure 11: Hypogonadism trials sponsors, by phase
LIST OF TABLES
11 Table 1: Marketed drugs for hypogonadism
16 Table 2: Pipeline drugs for hypogonadism in the US
21 Table 3: Historical global sales, by drug ($m), 2017–21
22 Table 4: Forecasted global sales, by drug ($m), 2022–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!